Diethyl 2-Propyl-1H-Imidazole-4,5-Dicarboxylate CAS 144689-94-1 Purity >99.0% (HPLC) Olmesartan Medoxomil Intermediate Factory

Short Description:

Diethyl 2-Propyl-1H-Imidazole-4,5-Dicarboxylate 

CAS: 144689-94-1

Purity: >99.0% (HPLC) 

Appearance: Pale Yellow to Off-White Powder 

Intermediate of Olmesartan Medoxomil 

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name Diethyl 2-Propyl-1H-Imidazole-4,5-Dicarboxylate
Synonyms Diethyl 2-PropylImidazoledicarbonate; 2-Propyl-1H-Imidazole-4,5-Dicarboxylic Acid Diethyl Ester; 2-Propylimidazoledicarboxylic Acid Diethyl Ester
CAS Number 144689-94-1  
CAT Number RF-PI1872
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C12H18N2O4
Molecular Weight 254.29
Density 1.160±0.06 g/cm3
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Pale Yellow to Off-White Powder
Purity / Analysis Method >99.0% (HPLC) 
Melting Point 83.0~88.0℃
Water Content (K.F) <0.50%
Residue on Ignition <0.20%
Maximum Single Impurity <0.50%
Total Impurities <1.00%
Proton NMR Spectrum Conforms to Structure
Test Standard Enterprise Standard
Usage Intermediate of Olmesartan Medoxomil (CAS: 144689-63-4)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

Diethyl 2-Propyl-1H-Imidazole-4,5-Dicarboxylate (CAS: 144689-94-1) is an intermediate in the synthesis of Olmesartan Medoxomil (CAS: 144689-63-4). Olmesartan Medoxomil is indicated for the treatment of high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Olmesartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). Olmesartan works by relaxing blood vessels so that blood can flow more easily. It may be used alone or in combination with other antihypertensive agents. The U.S. Food and Drug Administration (FDA) has determined that the benefits of Benicar continue to outweigh its potential risks when used for the treatment of patients with high blood pressure according to the drug label.

  • Write your message here and send it to us